Abstract
PURPOSE: We sought to investigate the safety and efficacy of intramuscular gene therapy with vascular endothelial growth factor (VEGF) in patients with chronic critical leg ischemia. METHODS: Gene transfer was performed in 24 limbs of 21 patients with rest pain, some of whom also had nonhealing ischemic ulcers (n = 16) due to occlusive peripheral arterial disease. Between 400 μg and 2000 μg of phVEGF165 (400 μg, n = 2; 800 μg, n = 4; 1200 μg, n = 4; 1600 μg, n = 6; and 2000 μg, n = 8) was injected directly into the muscles of the ischemic limb; the same dose was injected 4 weeks later. The ratio of blood pressures at the ankle and brachial artery was measured before and after treatment. RESULTS: Mean (± SD) plasma levels of VEGF increased significantly from 26 ± 31 pg/mL to 63 ± 56 pg/mL (P 165 for patients with chronic critical leg ischemia is safe, feasible, and effective.
| Original language | English |
|---|---|
| Pages (from-to) | 85-92 |
| Number of pages | 8 |
| Journal | American Journal of Medicine |
| Volume | 114 |
| Issue number | 2 |
| DOIs | |
| Publication status | Published - Feb 1 2003 |
| Externally published | Yes |
Fingerprint
ASJC Scopus subject areas
- Nursing(all)
Cite this
Intramuscular vascular endothelial growth factor gene therapy in patients with chronic critical leg ischemia. / Shyu, Kou Gi; Chang, Hang; Wang, Bao Wei; Kuan, Peiliang.
In: American Journal of Medicine, Vol. 114, No. 2, 01.02.2003, p. 85-92.Research output: Contribution to journal › Article
}
TY - JOUR
T1 - Intramuscular vascular endothelial growth factor gene therapy in patients with chronic critical leg ischemia
AU - Shyu, Kou Gi
AU - Chang, Hang
AU - Wang, Bao Wei
AU - Kuan, Peiliang
PY - 2003/2/1
Y1 - 2003/2/1
N2 - PURPOSE: We sought to investigate the safety and efficacy of intramuscular gene therapy with vascular endothelial growth factor (VEGF) in patients with chronic critical leg ischemia. METHODS: Gene transfer was performed in 24 limbs of 21 patients with rest pain, some of whom also had nonhealing ischemic ulcers (n = 16) due to occlusive peripheral arterial disease. Between 400 μg and 2000 μg of phVEGF165 (400 μg, n = 2; 800 μg, n = 4; 1200 μg, n = 4; 1600 μg, n = 6; and 2000 μg, n = 8) was injected directly into the muscles of the ischemic limb; the same dose was injected 4 weeks later. The ratio of blood pressures at the ankle and brachial artery was measured before and after treatment. RESULTS: Mean (± SD) plasma levels of VEGF increased significantly from 26 ± 31 pg/mL to 63 ± 56 pg/mL (P 165 for patients with chronic critical leg ischemia is safe, feasible, and effective.
AB - PURPOSE: We sought to investigate the safety and efficacy of intramuscular gene therapy with vascular endothelial growth factor (VEGF) in patients with chronic critical leg ischemia. METHODS: Gene transfer was performed in 24 limbs of 21 patients with rest pain, some of whom also had nonhealing ischemic ulcers (n = 16) due to occlusive peripheral arterial disease. Between 400 μg and 2000 μg of phVEGF165 (400 μg, n = 2; 800 μg, n = 4; 1200 μg, n = 4; 1600 μg, n = 6; and 2000 μg, n = 8) was injected directly into the muscles of the ischemic limb; the same dose was injected 4 weeks later. The ratio of blood pressures at the ankle and brachial artery was measured before and after treatment. RESULTS: Mean (± SD) plasma levels of VEGF increased significantly from 26 ± 31 pg/mL to 63 ± 56 pg/mL (P 165 for patients with chronic critical leg ischemia is safe, feasible, and effective.
UR - http://www.scopus.com/inward/record.url?scp=0037313811&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=0037313811&partnerID=8YFLogxK
U2 - 10.1016/S0002-9343(02)01392-X
DO - 10.1016/S0002-9343(02)01392-X
M3 - Article
VL - 114
SP - 85
EP - 92
JO - American Journal of Medicine
JF - American Journal of Medicine
SN - 0002-9343
IS - 2
ER -